ScreenerHero

PRCT PROCEPT BioRobotics Corporation

NAS · US · Healthcare · Medical Devices · procept-biorobotics.com
17.91USD+2.28%Mkt Cap: 1.03B $P/E: —

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$171.97BUSDP/E 31.8
MDT
Medtronic plc
$109.38BUSDP/E 21.0
SYK
Stryker Corporation
$105.64BUSDP/E 28.5
BSX
Boston Scientific Corporation
$60.26BUSDP/E 16.8
EW
Edwards Lifesciences Corporation
$49.39BUSDP/E 51.1
SHL
Siemens Healthineers AG
$46.91BUSDP/E 19.6
DXCM
DexCom, Inc.
$31.81BUSDP/E 33.5
GEHC
GE HealthCare Technologies Inc.
$29.42BUSDP/E 14.9
PHIA
Koninklijke Philips N.V.
$22.87BUSDP/E 18.7
PHG
Koninklijke Philips N.V.
$23.55BUSDP/E 18.0
STE
STERIS plc
$20.44BUSDP/E 25.6
SOON
Sonova Holding AG
$17.11BUSDP/E 28.0
ZBH
Zimmer Biomet Holdings, Inc.
$16.88BUSDP/E 21.5
PEN
Penumbra, Inc.
$12.46BUSDP/E 77.7
SNN
Smith & Nephew plc
$11.25BUSDP/E 18.3
DEMANT
Demant A/S
$9.87BUSDP/E 28.0
GKOS
Glaukos Corporation
$10.16BUSD
TXG
10x Genomics, Inc.
$9.92BUSD
GMED
Globus Medical, Inc.
$9.90BUSDP/E 18.9
BIO
Bio-Rad Laboratories, Inc.
$9.85BUSDP/E 46.6

Key Statistics

Company
Market Cap1.03B USD
Enterprise Value852.45M USD
Revenue (TTM)337.34M USD
Gross Profit196.23M USD
Net Income (TTM)-95.57M USD
Revenue/Share5.99 USD
Last Price17.91 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees888
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.19
PEG—
EV/EBITDA-7.74
EV/Revenue2.53
P/S2.97
P/B2.95
EPS (TTM)-1.94
EPS (Forward)-1.15
52W Range
16.675% of range39.86
52W High39.86 USD
52W Low16.67 USD
Profitability
Gross Margin63.70%
Oper. Margin-32.05%
EBITDA Margin-32.63%
Profit Margin-31.02%
ROE-26.12%
ROA-18.81%
Growth
Revenue Growth19.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.98M USD
CapEx (TTM)9.36M USD
FCF Margin-14.52%
FCF Yield-4.77%
Net Debt-150.41M USD
Net Debt/EBITDA1.37
Balance Sheet
Debt/Equity0.21
Current Ratio6.55
Quick Ratio5.23
Book Value/Sh5.94 USD
Cash/Share3.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.73 USD
Upside (mean)+21.3%
Target Range16.00 USD – 28.00 USD
16.00+21.3% to mean28.00
# Analysts11
Ownership
Shares Out.57.27M
Float55.81M
Insiders3.48%
Institutions100.50%
Short Interest
Short Ratio6.8d
Short % Float13.37%
Short % Out.12.99%
Shares Short7.44M
Short (prev mo.)7.71M
Technical
SMA 5019.86 (-9.8%)
SMA 20024.63 (-27.3%)
Beta0.92
S&P 52W Chg16.45%
Avg Vol (30d)1.22M
Avg Vol (10d)1.47M
Technical Indicators
RSI (14)43.2
MACD-0.8195
MACD Signal-0.7642
MACD Hist.-0.0552
BB Upper22.19 USD
BB Middle18.86 USD
BB Lower15.53 USD
BB Width35.30%
ATR (14)1.106 USD
Vol Ratio (20d)0.83x